Biological Factors – Page 6

Miniature Swine: Revolutionizing Nonclinical Studies for Small Molecules and Biologics

1 year ago talkbio0Tagged Biological Factors, dermal testing, Evaluation procedure, nonclinical studies, Safety, Scientific model, Small Molecule, Swine, Miniature

Miniature swine, Nonclinical studies, Small molecules, Biologics, Dermal testing, Safety assessments, Research models

Immunovant Shifts Focus to Next-Generation FcRn Inhibitor IMVT-1402, Delaying Batoclimab Development ###

1 year ago talkbio0Tagged Autoimmune Diseases, Batoclimab, Biological Factors, FCGRT gene, FcRn, Immunovant, IMVT-1402, Inhibitor, Roivant

Immunovant, IMVT-1402, FcRn inhibitor, Batoclimab, Autoimmune diseases, Vyvgart, Roivant, Biopharmaceuticals

Innovent Biologics’ Picankibart Achieves Success in Phase III CLEAR-1 Study for Moderate to Severe Plaque Psoriasis

1 year ago talkbio0Tagged Biological Factors, Center for Drug Evaluation, Chronic small plaque psoriasis, Class, drug application, Innovent, Interleukin-23 Subunit p19, Moderate (severity modifier), National Medical Product Administration, Phase III CLEAR-1 Study, picankibart

Innovent Biologics, picankibart, Phase III CLEAR-1 study, moderate to severe plaque psoriasis, IL-23p19 class, new drug application, Center for Drug Evaluation, National Medical Product Administration.

Revolutionizing Biotherapeutic Analysis: Novel icIEF Fractionation and Mass Spectrometry for Charge Characterization

1 year ago talkbio0Tagged analytical techniques, Biological Factors, biotherapeutics, Characterization, charge amounts, Chemical fractionation, Imaged Capillary Isoelectric Focusing, Protein Analysis, protein charge, Protein Purification, protein separation, therapeutic protein, Variant

biotherapeutics, icIEF fractionation, mass spectrometry, charge characterization, protein analysis, therapeutic proteins, biopharmaceuticals, analytical techniques, protein purification, protein separation, protein charge variants.

Tremfya Emerges as a Promising Successor to Stelara in J&J’s Pipeline with Robust Clinical Data

1 year ago talkbio0Tagged Biological Factors, Clinical Trials, head-to-head data, J&J, Psoriasis, Stelara, successor, Tremfya

J&J, Tremfya, Stelara, successor, head-to-head data, clinical trials, psoriasis treatment, biologics.

FDA Greenlights Biocon Biologics and Biogen’s Eylea Biosimilars: A New Era in Ophthalmology

1 year ago talkbio0Tagged Biocon, Biogen, Biological Factors, Biosimilars, Eylea, Ophthalmology specialty, regulatory approval, United States Food and Drug Administration

FDA, Eylea, biosimilars, Biocon Biologics, Biogen, ophthalmology, aflibercept, regulatory approval

Johnson & Johnson Expands into IL-13 and TSLP Market with Strategic Acquisition

1 year ago talkbio0Tagged Acquisition (action), Biological Factors, competition, Drug Industry, expansion, I&I, Inflammatory disorder, Interleukin-13, Johnson and Johnson, Market, strategic, TSLP gene

Johnson & Johnson, I&I acquisition, IL-13, TSLP, competitive market, strategic expansion, pharmaceutical industry, biologics, inflammatory diseases.

Innovent Scores Phase 3 Success with Lilly’s Pioneering Obesity Drug for Diabetes Management

1 year ago talkbio0Tagged Administration occupational activities, Biological Factors, Collaboration, Diabetes, Eli, Eli Lilly, GLUCOSE CONTROL, Innovent, Metabolic Diseases, next-generation therapy, Obesity, Phase 3 trials

Innovent Biologics, Eli Lilly, obesity drug, diabetes management, phase 3 trials, collaboration, metabolic disorders, weight loss, glucose control, next-generation therapy.